卡瑞利珠单抗联合化疗对晚期非鳞非小细胞肺癌患者 免疫功能和 NLR、CAR 的影响.

Objective: To investigate the effect of Camrelizumab combine with chemotherapy on immune function, neutrophil to lymphocyte ratio (NLR), C-reactive protein to albumin ratio (CAR) in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Methods: Used retrospective analysis, 100 patients with advanced non-squamous NSCLC who were admitted to the first affiliated hospital of Anhui medical university north district from January 2020 to December 2022 were selected, and patients were divided into control group (n=48) and observation group (n=52) according to the treatment methods. Control group received chemotherapy with pemetrexed disodium combined with cisplatin injection or nedaplatin for injection, and observation group received Camrelizumab treatment on the basis of control group. The efficacy, immune function, tumor markers, NLR, and CAR were compared between two groups, and the incidence of adverse reactions during treatment were observed simultaneously in two groups. Results: Compared with control group, the clinical total effective rate in observation group was higher (P<0.05). 4 cycles after treatment, compared with control group, the carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), carbohydrate antigen 125 (CA125), NLR, CAR and CD8+ in observation group were lower, while CD3+, CD4+ and CD4+/CD8+ were higher (P<0.05). There was no difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Patients with advanced non-squamous NSCLC combine with Camrelizumab treatment on the basis of chemotherapy, which is helpful to control disease progression, improve clinical efficacy, reduce tumor markers levels, improve immune function, and reduce NLR and CAR. [ABSTRACT FROM AUTHOR]